Bourgoin, France

Our facility in Bourgoin, France is an FDA-approved center of excellence for early- and late-stage development and commercial manufacturing for oral solid dose (OSD) products, with a specialization in handling highly potent APIs.

Early development hub

This 430-square-meter, dedicated R&D hub offers state-of-the-art equipment and industry-leading technologies to support formulation development and mature product characterization of OSD products.

This enables our customers to move from molecule to medicine to market faster by making data-driven decisions, minimizing trial-and-error experiments, and reducing risk on the development journey.

Site benefits include:

Integrated API production, solid state analysis, drug product development, clinical services, and regulatory support

• Simplified supply chain to help customers avoid costly delays
• Optimized manufacturing and scale-up to accelerate milestones
• Fewer tech transfers and improved site communication to optimize timelines

Bourgoin provides fast, flexible small-scale manufacturing alongside reliable full-scale processes. It serves as our primary EU site for the commercial manufacturing of OSD products.

Specialized capabilities:

• Early development of oral solid dose
• Specialized in handling highly potent APIs up to cat 3B, including cytostatic
• Packaging (bottles, blisters, speed line)
• Successful transfer and commercialization of development projects worldwide
• Manufacturing: Tablets, capsules, powders, and granules
• Orphan/niche indication product
• Non-sexual hormones
• Small scale production

Our Bourgoin site features a strong regulatory inspection history from all major international regulatory agencies. Additionally, we are committed to making ongoing investments in both capital and scientific resources at this location.

Learn more about our specific equipment and capabilities in Bourgoin by downloading our site fact sheet.